Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
Vir Biotechnology (Nasdaq: VIR) will hold its 2024 Annual Meeting of Stockholders on May 29, 2024, at 9:00 a.m. PT. The meeting will be conducted virtually via live audio webcast. Stockholders of record at the close of business on April 1, 2024, are eligible to attend and vote. Participants can access the meeting through the provided web link using their control number. Online access will begin at 8:45 a.m. PT on the day of the meeting. Vir Biotechnology encourages all stockholders to vote and submit their proxies in advance.
- Holding the meeting virtually increases accessibility for all shareholders.
- Clear instructions provided for attending and voting may boost participation.
- A virtual-only format may limit engagement for some shareholders.
- No new business updates or financial data shared in the announcement.
Vir Biotechnology’s stockholders of record at the close of business on April 1, 2024, the record date for the Annual Meeting, can attend and vote at the Annual Meeting by accessing the meeting center at www.virtualshareholdermeeting.com/VIR2024 and entering the control number on the proxy card or Notice of Internet Availability of Proxy Materials previously received. Instructions on how to connect to the Annual Meeting and participate via the Internet are also posted at www.virtualshareholdermeeting.com/VIR2024. Online access to the Annual Meeting will begin at 8:45 a.m. PT on May 29, 2024. Stockholders should allow ample time for the check-in procedures.
Whether or not stockholders plan to virtually attend the Annual Meeting, Vir Biotechnology urges them to vote and submit their proxy in advance of the Annual Meeting by one of the methods described in the proxy materials for the Annual Meeting.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is an immunology company focused on powering the immune system to transform lives by treating and preventing infectious diseases and other serious conditions, including viral-associated diseases. Vir has assembled two technology platforms that are designed to modulate the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information that may be important to investors on its website.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523355863/en/
Media
Carly Scaduto
Senior Director, External Communications
cscaduto@vir.bio
+1 314-368-5189
Investors
Richard Lepke
Senior Director, Investor Relations
rlepke@vir.bio
+1 978-973-9986
Source: Vir Biotechnology, Inc.
FAQ
When is Vir Biotechnology's 2024 Annual Meeting of Stockholders?
How can I attend the Vir Biotechnology 2024 Annual Meeting?
Who is eligible to vote at the Vir Biotechnology 2024 Annual Meeting?
When should I log in for the Vir Biotechnology 2024 Annual Meeting?
What should I do if I can't attend the Vir Biotechnology 2024 Annual Meeting?
